Intellisphere snaps up Ascend medical titles

Share this article:
Ascend Media has sold its struggling medical titles to Intellisphere for an undisclosed sum.

The Plainsboro, NJ-based publisher of MD Net Guide picks up The American Journal of Managed Care, Cardiology Review, Pharmacy Times, Resident & Staff Physician, Surgical Rounds, Family Practice Recertification, Internal Medicine World Report and Physician's Money Digest.

Overland Park, KS-based Ascend announced in December that it would shutter three titles—Physician's Money Digest, Family Practice Recertification and Internal Medicine World Report—and was considering selling the rest of its Princeton, NJ-based healthcare division due to weakness in the market for advertising on primary care titles.  

Last month, the firm sold its dental group to Aegis Communications. The publisher is holding onto its LA-based Allied Healthcare division, whose 14 specialty titles are more dependent on advertising from medical device manufacturers and service providers than from pharma.

Will Passano, who headed Ascend's Princeton healthcare unit, has left the company. The titles will be managed by Intellisphere president Brian Haug and Herb Marek, president and COO of Intellisphere parent MJH & Associates.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...